NCT04262856Phase 2Completed

Study to Evaluate Monotherapy and Combination Immunotherapies in Participants With PD-L1 Positive Non-small Cell Lung Cancer

Study sponsor: Arcus Biosciences, Inc. · RCUS

Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.

Open ClinicalTrials.gov record CSV export · Pro

Primary completion2025-07-09Actual

Enrollment · participants151Actual

Source updated2026-06-15Last update listed in the registry record

Version history

Changes to this trial

Last 12 months

Pro unlocks the full available history and CSV export. View Pro features

Posted 2026-06-10 · 1 field changed

Primary completion date changed

− Before

~~5 Jun 2025~~

+ After

9 Jul 2025

Check registry source

Study details

Conditions studied

Non Small Cell Lung Cancer; Nonsquamous Non Small Cell Lung Cancer; Squamous Non Small Cell Lung Cancer; Lung Cancer

Treatments or interventions studied

DomvanalimabDrugAlso known as AB154
EtrumadenantDrugAlso known as AB928
ZimberelimabDrugAlso known as AB122

Primary outcomes · main study measures

Read the study measures

measure: Objective response rate (ORR); description: ORR as assessed by RECIST v1.1; timeFrame: From randomization until the first documentation of disease progression or death from any cause, whichever occurs first (up to approximately 3-5 years); measure: Progression-free survival (PFS); description: PFS as assessed by RECIST v1.1; timeFrame: From randomization until the first documentation of disease progression or death from any cause, whichever occurs first (up to approximately 3-5 years)

History coverage

Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.

How to read this history